• P. N. Patsalos


Calcium carbonate and aluminum hydroxide do not affect the pharmacokinetics of levetiracetam [1].


Public Health Plasma Level Calcium Carbonate Oral Contraceptive Active Metabolite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–24.PubMedCrossRefGoogle Scholar
  2. 2.
    Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 2001;46:93–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Mink S, Muroi C, Bjeljac M, Keller E. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurismal subarachnoid haemorrhage. Clin Neurol Neurosurg. 2011;113:644–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85(2):77–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Sabers A, Christensen J. No effect of oral contraceptives on the metabolism of levetiracetam. Epilepsy Res. 2011;95:277–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 2001;47:55–63.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations